drugset / Trial / NCT05167825

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

NCT05167825

Phase 3 Completed 7 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.

Timeline

Start
2022-11-14
Primary completion
2024-08-23
Completion
2025-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Macitentan Other / unclassified Oral